KRAS and neoplasm: Additionally, STK11/LKB1 mutations cause resistance to PD-1 blockade in KRAS-mutated lung adenocarcinoma (19).The reduced antigen-presenting ability of tumor cells is characterized by abnormalities in MHC molecules.